IceCure Medical (NASDAQ:ICCM) Stock Price Down 4.4% – Time to Sell?

IceCure Medical Ltd (NASDAQ:ICCM) dropped 4.4% during trading on Monday . The company traded as low as $1.28 and last traded at $1.29. Approximately 202,105 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 508,000 shares. The stock had previously closed at $1.35.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $2.50 target price on shares of IceCure Medical in a research report on Wednesday, November 27th.

IceCure Medical Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.27 and a current ratio of 2.67. The stock’s 50-day moving average is $1.31 and its 200 day moving average is $0.94. The stock has a market capitalization of $73.82 million, a PE ratio of -4.59 and a beta of 0.37.

Institutional Trading of IceCure Medical

An institutional investor recently raised its position in IceCure Medical stock. XTX Topco Ltd increased its holdings in shares of IceCure Medical Ltd (NASDAQ:ICCM) by 123.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 58,866 shares of the company’s stock after purchasing an additional 32,555 shares during the period. XTX Topco Ltd owned 0.11% of IceCure Medical worth $65,000 as of its most recent SEC filing. 0.62% of the stock is owned by institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.